Show simple item record

dc.contributor.authorReck, M
dc.contributor.authorLuft, A
dc.contributor.authorSzczesna, A
dc.contributor.authorHavel, L
dc.contributor.authorKim, S
dc.contributor.authorAkerley, W
dc.contributor.authorPietanza, M
dc.contributor.authorWu, Y
dc.contributor.authorZielinski, C
dc.contributor.authorThomas, M
dc.contributor.authorFelip, E
dc.contributor.authorGold,K
dc.contributor.authorHorn, L
dc.contributor.authorAerts, J
dc.contributor.authorNakagawa, K
dc.contributor.authorLorigan, Paul C
dc.contributor.authorPieters, A
dc.contributor.authorKong Sanchez, T
dc.contributor.authorFairchild, J
dc.contributor.authorSpigel, D
dc.date.accessioned2016-10-12T12:53:35Z
dc.date.available2016-10-12T12:53:35Z
dc.date.issued2016-07-25
dc.identifier.citationPhase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. 2016: J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid27458307
dc.identifier.doi10.1200/JCO.2016.67.6601
dc.identifier.urihttp://hdl.handle.net/10541/619938
dc.description.abstractPatients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titlePhase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.en
dc.typeArticleen
dc.contributor.departmentMartin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf;en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPatients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC.


This item appears in the following Collection(s)

Show simple item record